Navigating First- and Second-Line Therapies in Extensive-Stage Small Cell Lung Cancer

Panelists discuss the diagnostic evaluation and staging process for extensive-stage small cell lung cancer, emphasizing comprehensive imaging and laboratory workup to guide initial treatment planning.

Panelists discuss how patient and disease factors, such as performance status, comorbidities, and extent of metastases, influence first-line treatment selection in small cell lung cancer.

Panelists review key clinical trial data demonstrating the efficacy and safety of chemo-immunotherapy regimens in extensive-stage small cell lung cancer.

Panelists discuss practical considerations in selecting first-line regimens and managing maintenance therapy in patients responding to initial treatment.

Panelists discuss the clinical relevance of emerging trial data evaluating combination maintenance strategies and their potential role in practice.

Panelists discuss therapeutic strategies for recurrent small cell lung cancer with central nervous system involvement, emphasizing adverse event (AE) management and patient support.

Panelists discuss the importance of shared decision-making, patient communication, and adherence strategies in small cell lung cancer treatment.

Panelists discuss treatment decision-making in second-line small cell lung cancer, balancing efficacy, toxicity, and patient-specific factors.

Panelists discuss real-world experiences with novel agents for relapsed small cell lung cancer, focusing on efficacy, safety, and patient selection.

Panelists discuss novel and investigational therapies under study for small cell lung cancer, including immunotherapy combinations and targeted approaches.